WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017176760) METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/176760    International Application No.:    PCT/US2017/025951
Publication Date: 12.10.2017 International Filing Date: 04.04.2017
IPC:
A61K 39/395 (2006.01), C07K 16/28 (2006.01), C07K 16/46 (2006.01), C12N 5/078 (2010.01)
Applicants: SANDLER, Vladislav [US/US]; (US)
Inventors: SANDLER, Vladislav; (US)
Agent: LUBIT, Beverly, W.; (US)
Priority Data:
62/317,906 04.04.2016 US
Title (EN) METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES
(FR) PROCÉDÉ D'ÉLIMINATION DE CELLULES SOUCHES HÉMATOPOÏÉTIQUE/PROGÉNITEURS HÉMATOPOÏÉTIQUES (CSH/PH) CHEZ UN PATIENT À L'AIDE D'ANTICORPS BISPÉCIFIQUES
Abstract: front page image
(EN)The described invention provides compositions containing bi-specific antibodies that bind to human tyrosine kinase receptor FLT3/FLK2 receptor protein and to CD3 receptor protein expressed on T-cells and use of the compositions containing the bispecific antibodies in the preparation of a medicament for eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient.
(FR)La présente invention concerne des compositions contenant des anticorps bispécifiques qui se lient à la protéine de récepteur de tyrosine kinase humaine FLT3/FLK2 et à une protéine de récepteur de CD3 exprimée sur des lymphocytes T et l'utilisation des compositions contenant les anticorps bispécifiques dans la préparation d'un médicament destiné à éliminer des cellules souches hématopoïétiques/progéniteurs hématopoïétiques (CSH/PH) chez un patient.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)